Neutralizing antibodies are a type of acquired immune system proteins produced by B cells that can bind to or neutralize pathogenic microbes like viruses or their toxic products, usually by blocking receptor binding or enzymatic activity required for pathogen invasion and spread. There are various medical applications of neutralizing antibody including use in passive immunization to prevent or treat infectious diseases and its emerging popularity in the treatment of COVID-19 infections.

The global Neutralizing Antibody Market is estimated to be valued at US$ 1.87 Billion in 2024 and is expected to exhibit a CAGR of 4.9% over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights.

Market Opportunity:
Emerging Popularity in the Treatment of COVID-19
The development and approval of neutralizing antibodies as specific treatment for COVID-19 infections is expected to significantly boost the overall market growth over the forecast period. Sotrovimab by GlaxoSmithKline received FDA emergency use authorization in May 2021 as monoclonal antibody treatment for mild-to-moderate COVID-19 in adults and pediatric patients. Moreover, the clinical efficacy demonstrated by sotrovimab against SARS-CoV-2 variants of concern increases its popularity as an effective treatment option. It is estimated that rising cases of COVID-19 around the world along with growing applications of neutralizing antibodies as therapeutics for the disease will continue drive the demand.

Porter's Analysis

Threat of new entrants: Low as high R&D costs and regulatory barriers make market entry difficult.

Bargaining power of buyers: Moderate as few dominant players exist but alternate treatment options provide leverage.

Bargaining power of suppliers: Moderate as key inputs require specialized expertise and scale provides advantage.

Threat of new substitutes: Low as no major substitute exists for neutralizing antibody therapeutics.

Competitive rivalry: High as major players compete on innovation and production scale.

SWOT Analysis

Strengths: Growing aging population and advancements in recombinant technology. Weaknesses: High development costs, regulatory approvals, manufacturing challenges. Opportunities: Untapped potential in emerging markets, ARDS and COVID-19 treatment. Threats: Patent expiries, biosimilar competition, supply chain disruptions.

Key Takeaways

The global Neutralizing Antibody Market is expected to witness high growth over the forecast period of 2024 to 2031. Global Neutralizing Antibody Market Size is estimated to be valued at US$ 1.87 Billion in 2024 and is expected to exhibit a CAGR of 4.9% over the forecast period 2024 to 2031.

North America currently dominates due to presence of major companies and higher adoption. However, Asia Pacific is expected to grow at the fastest pace supported by improving healthcare infrastructure, expanding R&D capabilities and growing medical tourism in countries like China and India.

Key players operating in the Neutralizing Antibody market are Mohawk, Pfizer, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, AstraZeneca, Novartis, Sanofi, Johnson & Johnson, Bristol-Myers Squibb, AbbVie, Bausch Health, GSK, Teva Pharmaceutical. Regional governments especially in Asia Pacific are collaborating with these players through initiatives targeting capacity building and technology transfer.

Get More Insights on this Topic- https://www.marketwebjournal.com/neutralizing-antibody-market-forecast-outlook-and-growth/